Serum Levels and Cardiovascular Effects of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors in Depressed Patients
Authors:
- Jan DreherJDJan Dreher
- Iaroslav MalevanyIMIaroslav Malevany
- Metin BagliMBMetin Bagli
- Martin KolbingerMKMartin Kolbinger
- Heyder OmranHOHeyder Omran
- Berndt LüderitzBLBerndt Lüderitz
- Marie Luise RaoMRMarie Luise Rao
- 1 August 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 23 (4) , 435-440
Abstract
Tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) are used to treat depression. Whereas cardiovascular effects have occasionally been reported during controlled studies with SSRIs, TCA treatment poses a well-known problem in this respect. To investigate the putative correlation between antidepressant dose or serum levels and adverse effects, the authors devised a naturalistic study to evaluate the tricyclic antidepressants' and SSRIs' effect on the cardiovascular system. The authors also compared antidepressant serum levels to adverse effects. Inpatients treated with TCAs or SSRIs were included; an electrocardiogram (ECG) and a Schellong test were carried out on the day patients entered the hospital and during steady-state treatment with antidepressant drugs when blood was drawn for therapeutic drug monitoring. The patient population consisted of 114 acutely depressed patients; 81 patients were treated with TCAs and 33 with SSRIs. The TCAs comprised amitriptyline (n = 43), clomipramine (n = 11), doxepin (n = 19) and imipramine (n = 8); the SSRIs comprised fluvoxamine (n = 14) and paroxetine (n = 19). In TCA-treated patients, the authors observed the same type of abnormalities in conduction and orthostatic hypotension as had been observed earlier. The authors also observed cases of first-degree atrioventricular block, prolonged QTc interval, and orthostatic hypotension in SSRI-treated patients. Thus SSRIs also appear to affect the cardiovascular system, which might pose a problem for patients with preexisting conduction disease. The authors observed a strong correlation between the decrease in systolic pressure and antidepressant serum concentration (except for clomipramine and paroxetine), suggesting that antidepressant serum level is a better correlate than dose.Keywords
This publication has 23 references indexed in Scilit:
- Determination of Fluvoxamine and Paroxetine in Human Serum with High-Performance Liquid Chromatography and Ultraviolet DetectionJournal of Liquid Chromatography & Related Technologies, 1997
- A Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patientsThe British Journal of Psychiatry, 1991
- 2-Hydroxydesipramine and Desipramine Plasma Levels andJournal of Clinical Psychopharmacology, 1991
- Use of Fluoxetine in a Person With Cardiac ArrhythmiasPsychosomatics, 1990
- Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolitesActa Psychiatrica Scandinavica, 1989
- Cardiovascular Toxicity of Antidepressant MedicationsPsychopathology, 1987
- FluvoxamineDrugs, 1986
- Cardiovascular Effects of Tricyclic Antidepressants in Depressed Patients with Chronic Heart DiseaseNew England Journal of Medicine, 1982
- Comparison of Imipramine- and Nortriptyline-Induced Orthostatic HypotensionJournal of Clinical Psychopharmacology, 1981
- The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations.Circulation, 1979